MedTrace Logo

A Multi-institution Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study)

NCT07582276 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-05-12

No results posted yet for this study

Summary

This study is comparing bone mineral density in patients with Severe Hemophilia A on Emicizumab prophylaxis vs patients on Efanesoctocog alfa prophylaxis

Conditions

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    collaborator INDUSTRY

  • Arkansas Children's Hospital Research Institute

    lead OTHER

Principal Investigators

  • Divyaswathi Citla Sridhar, MD · Arkansas Children's Reserach Institute

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2031-08-01
Completion
2032-08-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07582276 on ClinicalTrials.gov